Custom MRD Panels
MRD panel 680x680

Longitudinal monitoring for minimal residual disease (MRD)

Cell3™ Target: Custom MRD Panels

Small, ultrasensitive, personalized next generation sequencing (NGS) panels for detecting tumor specific variants at multiple time points.

Personalized panels designed in minutes

An on-line panel design tool and rapid manufacture process enables fast turnaround of highly targeted tumor specific NGS panels.

Cost effective at high depth

High on-target rates and superior uniformity of coverage, makes sequencing cost effective for depths of 20,000x and above.

Ultrasensitive tumor variant detection

Confidently call mutations down to 0.1% variant allele frequency (VAF) from as little as 25 ng cell-free DNA (cfDNA).

Streamlined liquid biopsy workflow

From sample collection through to sequencing, our liquid biopsy workflow provides a streamlined solution for longitudinal monitoring of MRD.

Minimal residual disease

MRD is defined as a very small number of cancer cells that remain in the body during or after treatment. Being able to detect and measure MRD may help to inform how well a treatment is working and detect the return of cancer in a patient. Current standard of care methods for measuring MRD post treatment, like imaging or tumor biopsy testing, rely on significant disease progression before they can be effective. This wastes precious time.

Liquid biopsy offers a more sensitive and less invasive method for detecting MRD. Used to measure the presence of cell-free circulating tumor DNA (ctDNA) released by cancer cells primarily into the bloodstream, liquid biopsies provide a snapshot of tumor cell evolution. Through analyzing repeated liquid biopsy samples over time, it is possible to carry out longitudinal monitoring of cancer patients and accurately measure the presence of MRD.

Diagram depicting the shedding of circulating tumor DNA (ctDNA) in the bloodstream from a primary tumor

Custom NGS panels for MRD

Longitudinal monitoring and the early detection of minimal residual disease requires the detection of low levels of ctDNA against a background of normal cfDNA. Small, targeted NGS panels allow multiple tumor-specific mutations to be sequenced to an extremely high depth of coverage providing the sensitivity necessary for liquid biopsy MRD detection without becoming prohibitively expensive.

Cell3 Target Custom panels for MRD combine the benefits of our proven Cell3 Target technology with smaller panel designs. This ensures faster turnaround times and lower costs whilst still including sufficient variants for MRD detection.

DNA-hand 680x616

Personalized panels designed at the touch of a button

Designing small, highly customizable NGS panels which deliver excellent uniformity of coverage and high on-target rates can be challenging. Our cloud-based Panel Design Tool leverages all of our experience and expertise in an online software tool to deliver great probe design, first time.

In minutes you can design an NGS panel targeting the variants you want to monitor. Using integrated algorithms, the tool automatically masks highly repetitive regions ensuring that the probes in each design cover target regions with superior uniformity of coverage.

All of this ensures that you are not spending money over sequencing some regions to ensure coverage of other poorly covered regions.

Sensitivity without breaking the bank

Delivering the sensitivity needed to detect MRD requires very deep sequencing, often to raw read depths in excess of 20,000x.

At this depth, sequencing efficiency becomes critical to ensure you only spend valuable budget on sequencing regions that you actually want to analyze.

Cell3 Target enrichment technology has been optimized to deliver efficient target capture and unrivalled probe performance regardless of panel size:

  • High on-target rates and uniformity of coverage even on panels <500 probes in size
  • Confident calling of variants at 0.1% VAF from as little as 25 ng cfDNA input without breaking the bank
Cell3 Target uniformity and low coverage performance compared to reported sensitivity of cytology and cystoscopy

A complete workflow for longitudinal monitoring

From sample collection through to bioinformatic analysis, Nonacus provides an optimized liquid biopsy workflow to ensure sensitive detection of ctDNA.

  • Specialized cfDNA blood collection tubes for liquid biopsy applications
  • Manual and automated extraction kits optimized and validated for cfDNA
  • Online panel design tool
  • Streamlined NGS library preparation protocols suitable for automation
  • Optimized hybridization and capture panels

For Research Use Only. Not for use in diagnostic procedures. 

See our customer publications

Cell3™ Target panels are available with one of two versions of our library preparation kits:

  • Fragmentation: for use with DNA (genomic, FF, FFPE)
  • Non-fragmentation: for use with cell-free DNA

Panel Size - XS50-500 probes
48 SamplesNGS_C3C_XS_FR_48NGS_C3C_XS_NF_48
96 SamplesNGS_C3C_XS_FR_96_A/B/C/D*NGS_C3C_XS_NF_96_A/B/C/D*
Panel Size - S501-1000 probes
48 SamplesNGS_C3C_S_FR_48NGS_C3C_S_NF_48
96 SamplesNGS_C3C_S_FR_96_A/B/C/D*NGS_C3C_S_NF_96_A/B/C/D*

* To provide flexibility in multiplexing samples, our 96-sample kits offer a choice in adapter plate:

A = Adapter plate with indexes 1-96
B = Adapter plate with indexes 97-192
C = Adapter plate with indexes 193-288
D = Adapter plate with indexes 289-384

Interested in our Cell3™ Target: Custom MRD Panels?